Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ICMT | O60725 | 14/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423426 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL8025173 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL5433147 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL664393 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL5274733 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1648111 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL4024890 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL2818639 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1648108 | 1.00 | MAPT (1.00) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1762100 | 0.99 | MAPT (0.97) | MAPTALDH1A1ICMTMEN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108852927-A | A kind of pox-dispelling function skin care compositions and its application containing growth factor | 广东科玮生物技术股份有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20100247461-A1 | ANTI-INFLAMMATORY COMPLEXES | SIGNUM BIOSCIENCES, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | BHMT, BHMT2, GNMT | MAPT 2122/4885ALDH1A1 811/4885ICMT 7/4885 |
| US-20100247461-A1 | ANTI-INFLAMMATORY COMPLEXES | SSB, NFKBIA, FABP1 | MAPT 2899/4885ALDH1A1 1904/4885ICMT 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.